RYC(SZ:003010) Hua Yuan Zheng Quan·2026-01-29 07:55Investment Rating - The investment rating for the company is "Accumulate" (maintained) [4] Core Views - The company's performance forecast for 2025 aligns with expectations, with proprietary brand revenue expected to achieve high growth [4] - Significant growth in net profit is anticipated due to rapid revenue growth from proprietary brands, strong performance in brand management, and effective cost reduction strategies [6] - The company has established a competitive advantage in various categories, including health products, maternal and infant care, beauty and personal care, and food and beverages, which may further enhance growth potential [6] Financial Summary - Revenue projections for the company are as follows: - 2023: 1,366 million RMB - 2024: 1,766 million RMB (growth of 29.26%) - 2025: 2,934 million RMB (growth of 66.14%) - 2026: 4,374 million RMB (growth of 49.11%) - 2027: 5,401 million RMB (growth of 23.47%) [5] - Net profit forecasts are as follows: - 2023: 54 million RMB - 2024: 106 million RMB (growth of 94.58%) - 2025: 190 million RMB (growth of 79.67%) - 2026: 327 million RMB (growth of 72.07%) - 2027: 459 million RMB (growth of 40.51%) [5] - Earnings per share (EPS) projections are: - 2023: 0.17 RMB - 2024: 0.34 RMB - 2025: 0.61 RMB - 2026: 1.05 RMB - 2027: 1.48 RMB [5] Business Strategy - The company is focusing on enhancing its proprietary brand business, with successful product launches contributing to revenue growth [6] - The brand management business is also expected to see significant performance improvements through deep collaborations with multiple brands [6] - The company is implementing a refined operational strategy to optimize costs across various dimensions, including supply chain management and marketing [6]